A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. - Wikidata - wikimedia - TriplyDB

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

http://www.wikidata.org/entity/Q33886553

about

Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes Muscle-invasive urothelial bladder cancer: an update on systemic therapy Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome.Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value.Identification of mutations in distinct regions of p85 alpha in urothelial cancer.Novel molecular targets for urothelial carcinoma PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest.DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.Should Gleason 6 be labeled as cancer?Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.Exploring molecular genetics of bladder cancer: lessons learned from mouse models Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Emerging personalized approaches for the management of advanced urothelial carcinoma.Molecular targets on the horizon for kidney and urothelial cancer.Emerging drugs for urothelial carcinoma.New treatments for bladder cancer: when will we make progress?Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine.TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.Effect of PTEN Gene Mutations and Environmental Risk Factors on the Progression and Prognosis of Bladder Cancer.Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3.Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p.PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.Reply to S. Buti and S. Culine.EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder.Oncogenic mutations in extramammary Paget's disease and their clinical relevance.PI3K/AKT pathway activation in bladder carcinogenesis.Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression.Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance.Bladder cancer.A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

P2860

Q26765922-4E6A3832-CF2B-4B62-8778-420BE51B3710 Q26775780-9BAA58C2-7C2E-4FE7-AC9F-9838417256F9 Q30857433-1F70B670-9F7E-4B50-BDA7-9253A571128C Q33915396-7BB2B062-4CC3-4499-B6EC-3EEB40A3EEFE Q34299788-17616D07-83C7-472D-ABF0-257D07AAFD15 Q34565346-7A868991-A0D7-4D50-8949-B2369B86D75E Q34674350-7B881CC6-61BC-4B77-9EA7-536EDD6DDE35 Q35075756-7549A66B-827B-4DFA-ACC1-2EE8E0A0E259 Q35527068-D758B1B1-705C-4742-BC3D-FA5E9A65D6FB Q36087843-A904978A-0693-4F68-B507-8F5C5B5A0170 Q36140798-FEF79320-85B7-452E-A295-A863BD97AC26 Q36187834-8D767A54-5249-4748-A7A8-CCF85FE7D113 Q36665063-EBC939DB-71AE-4EF4-B3EC-DD55AEFAE1FD Q36931932-0B9B8982-18F3-435E-A7CE-8F8588384265 Q37053820-D57C4468-EF5C-47D2-BE3C-F0781505FA10 Q37457496-61ED5E10-566F-41E8-8B98-07294BB6F567 Q37612632-D666BDAC-6211-45A6-AB73-5ACA8ED527CE Q37994164-5D206EC9-39D8-4D86-8979-2E7029D534FF Q38042638-7C79502B-5F90-4913-A75B-37582943CAA4 Q38068583-AC8CFB41-4D96-4174-99CE-C93DC7D729BC Q38132039-7FA91FE9-2298-44A0-9A08-7928BDE36F28 Q38160271-07B44082-6C45-41C6-98B8-41316690B775 Q38177753-EFB69E1C-4B79-4FDA-8116-06DB5FB9F5CF Q38297729-D0CF46F0-70B4-44B5-BD91-508C61DBE566 Q38929614-7D0CD6F2-4A1A-458A-87CE-13453BF144FF Q39196241-3F0E6DDB-A310-4C73-B876-82578EF732E1 Q40850887-B9B445F4-083C-4E52-9406-A0679DB99DAE Q40984224-D509AAD0-9F60-4994-BB3C-61A6A631CCD7 Q41584915-78442FC8-DFED-46A5-977E-E510401311E9 Q41947839-500132DB-39A9-4084-9F0F-08260A5970E2 Q42798110-22A04E9A-3DAF-42BB-A6C9-2FF7D1F54F8C Q43196463-61A55081-EFB4-4636-A1E7-5482F9C610E5 Q45901176-B14AA9DB-E2DC-4CE5-9603-9D463589FD48 Q46574069-AB38D826-0EBB-4DF9-BBB0-C941FC6778CB Q46976450-44897330-409E-49B6-B7A8-7E6982651923 Q47232136-8EEBA8BE-CABA-414C-9E5D-C9C24AE31487 Q49886956-3811D87E-26B7-4B3F-BF1C-8BD9ABC52FE5 Q52810295-D88C4F8E-D488-4A86-9DB9-0AF538869621 Q54285690-58C67BA7-282E-412F-BF10-32425C9FAFF6

P2860

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

http://www.wikidata.org/entity/Q33886553

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A systematic study of gene mut ...... mutations in TSC2 and PIK3R1.

@ast

A systematic study of gene mut ...... mutations in TSC2 and PIK3R1.

@en

type

label

A systematic study of gene mut ...... mutations in TSC2 and PIK3R1.

@ast

A systematic study of gene mut ...... mutations in TSC2 and PIK3R1.

@en

prefLabel

A systematic study of gene mut ...... mutations in TSC2 and PIK3R1.

@ast

A systematic study of gene mut ...... mutations in TSC2 and PIK3R1.

@en

P1433

Q33886553-A9F43830-14C7-40B4-BF54-5A0A4A9B3539

P1476

Q33886553-36C12777-3EC4-4A18-8246-CB38DE9FC28F

P2093

Q33886553-2BF32981-0078-4944-BB56-549587D03032

Q33886553-4B75A9A0-B5B4-447A-89A7-B7AA7AFEE224

Q33886553-4CB9ADCA-1F7F-44FC-8624-45E736CBE849

Q33886553-52058055-383D-4329-A5C9-B6628BEDE1A5

Q33886553-C0A8ECE4-CC5E-4009-A0E9-D209E87F1E62

Q33886553-C38ED806-3336-452C-AFC2-332F1E448FBE

P2860

Q33886553-05144D61-493C-4867-9DCC-20BD3CCC9B24

Q33886553-12F8EB88-6330-4C8D-A1B8-2F6451766865

Q33886553-1F0728B6-37BB-4691-BCBD-693ABEB3638D

Q33886553-25C53E8F-D2A2-4013-BE2B-0BCD59B2D3D2

Q33886553-2729F0C1-8C07-4B78-82F6-EAB63C416FBC

Q33886553-2DE7F5AB-43A7-4C7D-9076-7AA7BD105ADC

Q33886553-2E981E88-C519-4430-BC5C-D0A93AB3B289

Q33886553-302E57E0-49AB-4935-9297-B8C12D168E3C

Q33886553-34664F09-BB8B-4EEA-9E4A-68D51D062FA3

Q33886553-4079E3C8-D3F3-43AF-AAED-7F6EF156C532

P304

Q33886553-BE9C334B-173D-4962-B6AB-2A7F35777B4F

P31

Q33886553-1780CC07-76C7-4024-BFA1-CF70A40699EA

P356

Q33886553-D44431A9-0E90-4EB8-96F0-9B3C5C99FCFA

P407

Q33886553-CE217934-4FDF-471E-90A6-F6A603401F1A

P433

Q33886553-79B713B5-3155-456A-AC76-504AF68C16EB

P478

Q33886553-03BEEE70-DFEC-49CA-9DC8-3167424D8DFA

P50

Q33886553-B767CC44-C52B-4215-A704-B6BFA220A72A

Q33886553-D58C50E8-B9AE-4D5D-B68C-6496BE4FEE9A

Q33886553-ECD62CEB-71B7-46D5-9831-4F6E86BC5B11

P577

Q33886553-AE2D7C1E-57BB-4F83-94FD-B6EFF57CFF80

P5875

Q33886553-B5885D02-6C77-495D-A11C-8BF2C243AA0E

P698

Q33886553-DDC74B63-2C05-4088-BF86-3B3D4E1FFFD2

P932

Q33886553-068E9BA8-A34B-49A3-92D3-FC40B3975A75

P356

JOURNAL.PONE.0018583

P1433

P1476

A systematic study of gene mut ...... g mutations in TSC2 and PIK3R1

@en

P2093

Christer Halldén

http://www.w3.org/2001/XMLSchema#string

David Lindgren

http://www.w3.org/2001/XMLSchema#string

Fredrik Liedberg

http://www.w3.org/2001/XMLSchema#string

Gunilla Chebil

http://www.w3.org/2001/XMLSchema#string

Martin Lauss

http://www.w3.org/2001/XMLSchema#string

Wiking Månsson

http://www.w3.org/2001/XMLSchema#string

P2860

Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors

An integrated genomic analysis of human glioblastoma multiforme

A method and server for predicting damaging missense mutations

The tuberin-hamartin complex negatively regulates beta-catenin signaling activity

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.

Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

P304

e18583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0018583

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Mattias Höglund

Sigurdur Gudjonsson

Gottfrid Sjödahl

P577

2011-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51089367

http://www.w3.org/2001/XMLSchema#string

P698

21533174

http://www.w3.org/2001/XMLSchema#string

P932

3077383

http://www.w3.org/2001/XMLSchema#string